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Aims. To compare methylation proﬁles, protein expression, and microsatellite instability (MSI) of sporadic, HNPCC, and familial
hyperplastic polyps (HPs). Methods. Methylation-speciﬁc PCR (MSP) and pyrosequencing assessed p16, MGMT, hMLH-1, MINT
1, and MINT 31 methylation. IHC (Immunohistochemistry) assessed Ki67, CK20, hMLH-1, hMSH-2, and hMSH-6 protein
expression. MSI analysis was performed on those polyps with adequate DNA remaining. Results. 124 HPs were identiﬁed 78
sporadic, 21 HNPCC, 25 familial, and the HNPCC group demonstrated no signiﬁcant diﬀerences in overall methylation (P = .186
Chi2). The familial group demonstrated signiﬁcantly less over all methylation levels (P = .004 Chi2). Conclusions.H P st h a to c c u r
in HNPCC have no more worrying features at a molecular level than those patients with HPs in a sporadic setting.
1.Introduction
For many years hyperplastic polyps (HPs) have been consid-
ered innocuous lesions. Recent pathological and molecular
observations have challenged this and given rise to the
serratedadenomacarcinomasequence.Priortothis,theade-
nomacarcinomasequencewasbelievedtobethemechanism
by which most or all colorectal cancer (CRC) occurred; this
sequence described a series of mutations in genes resulting in
an increasingly dysplastic adenoma progressing to CRC over
time.However,thereportedaccumulationofgeneticchanges
described in the adenoma-carcinoma sequence [1]d o e sn o t
wholly account for neoplastic transformation within the
colon [2–4].
Mutation of the mismatch repair genes (most commonly
MLH-1 and MSH-2) leading to MSI (microsatellite instabil-
ity) in CRC is an alternative mechanism underlying tumour
formation in patients with HNPCC [5]. It is now known
that up to 15% of sporadic CRC also have MSI; not as a
consequence of mutation in the mismatch repair genes but
through a process of epigenetic changes to MLH-1 [6].
Epigenetics describes the silencing of key tumour sup-
pressor genes through methylation of cytosine residues in
the promoter regions of DNA [7]. Methylation occurs in
up to 30% of CRC [8]. Hyperplastic polyps and serrated
adenomas (SAs) have also been demonstrated to develop as a
consequence of methylation. That methylation is present in
HPs, SAs, and 30% of CRC without the series of mutations
described in the adenoma carcinoma sequence has led to the
suggestion of a serrated neoplasia pathway [7, 8].
A number of known genes are silenced in cancer
by methylation including MLH-1, p16INK4a,M G M T ,a n d
MINT 1 and 31. Methylation aﬀects gene expression in a
graded fashion, a threshold of 15% promoter methylation
is considered biologically signiﬁcant [9–11]. The number of
genes methylated can be described by CiMP (CpG island
m e t h y l a t e dp h e n o t y p e ) :C i M PS ,n om e t h y l a t i o n ;C i M PL ,
one gene methylated, and CiMP H, more than one gene
methylated [11, 12].
Most studies of sporadic HPs are either on patients with
hyperplastic polyposis or selected HPs based on location in
the colon or size. It is known that methylation is a frequent2 International Journal of Surgical Oncology
Figure 1: Low-powered view of a typical HP processed for the
study.
e v e n ti ns p o r a d i cH P s[ 13, 14]; however, the true incidence
of methylation in HPs from a sporadic unselected cohort
remains unknown. In the HNPCC screening program at
Manchester Royal Inﬁrmary 49% of polyps detected were
HPs or SAs [15]. There are few papers describing the
incidence of HPs in HNPCC and incomplete data regarding
the molecular proﬁles of these lesions [16–18]. Mismatch
repairmutationsareconsideredthepathwaybywhichcancer
develops in patients with HNPCC. There is no evidence
to date that those HPs that occur in HNPCC arise as a
consequence of germline mismatch repair mutation and
therefore should arise as a consequence of methylation like
there sporadic counterparts. The methylation proﬁle of HPs
andSAsinpatientswithafamilyhistoryofCRCisunknown.
This study analyses methylation proﬁles of HPs which arise
in patients with a greater than 1:10 empiric risk of CRC
(familial group), patients with HNPCC, and patients who
develop HPs sporadically. In addition Ki-67 and CK-20
immunostaining has been performed to analyse mucosal
proliferationanddiﬀerentiationaspreviouslydescribed[19–
21].
2. Methods
2.1. Subjects and Recruitment. Patients were recruited with
informed consent via the Manchester Royal Inﬁrmary
Endoscopy Unit (sporadic) and the regional genetics service
HNPCC database (familial and HNPCC). Sporadic hyper-
plasticpolypsweredeﬁnedaspolypsoccurringinindividuals
without a family history of colorectal cancer; these contained
an unselected 12-month cohort of specimens. Familial
polyps were deﬁned as polyps occurring in individuals with
a greater than 1:10 empiric risk of CRC; their risk of was
obtained from genetic records and scrutiny of pedigrees.
Patients with HNPCC were identiﬁed via the regional
genetics service. Ethical approval was obtained from South
Manchester LREC 05/Q1403/109. All slides were reviewed by
a consultant histopathologist to conﬁrm presence of HPs in
the tissue blocks (Figure 1).
2.2. Methylation Analysis. DNA extraction from paraﬃn
embedded tissue was performed with a DNeasy kit (Qiagen
Crawley, UK). Bisulﬁte modiﬁcation of polyp DNA was per-
formed using an EZ DNA methylation kit (Zymo Research,
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Figure 2: Pyrograms for MINT 1. (a) Represents unmethylated
control bisulﬁte modiﬁed DNA. Position 2 represents the quality
control loci and should remain negative for Cs. It can be seen that
all Cs within the CpG islands at positions 1, 3, and 4 also reveal
no Cs, that is, the DNA is unmethylated. In contrast, pyrogram
B which represents a positive control from the SW48 cell line,
position 2 remains negative for Cs, but the CpG’s at position 1,
3, and 4 have 64.1%, 87.5%, and 83.9% methylation, respectively.
This positive control as anticipated is methylated. The ﬁnal sample
in C represents DNA extracted from a hyperplastic polyp. This
demonstrates 20.6%, 27.3%, and 28.1% methylation at position 1,
3, and 4, respectively, with a negative result for the internal control
at position 2.
California, USA). Methylation analysis was performed with a
combinationofmethylationspeciﬁcPCR(MSP)forp16INK4a
and MGMT, and MLH-1 and pyrosequencing for MINT
1 and MINT 31. Both methods have been previously well
described [22–25]. Negative controls were generated from
leukocyteDNAandpositivecontrolsfromtheSW48cellline.
The primers and PCR conditions for MSP are described in
Tables 1–4. Greater than 15% methylation was considered
biologically signiﬁcant when quantiﬁable techniques were
employed.
For methylation analysis of MINT 1 and MINT 31,
primers were designed for the designated sequence as
described by Toyota using pyrosequencing softwareprovided
by biotage (www.biotagebio.com), Table 5 and Figure 2 [11,
25]. The accuracy of pyrosequencing was conﬁrmed by gen-
erating standard curves as previously described [25]. Pyrose-
quencing generated quantiﬁable results for methylation, a
15% threshold for methylation was considered biologicallyInternational Journal of Surgical Oncology 3
Table 1: Primers used in the ampliﬁcation of CpG islands from bisulﬁte-treated DNA by PCR (nested PCR) including their sequences and
annealing temperature.
Gene Genbank accession
number Sense primer Antisense primer Annealing
temp (◦C)
P16
INK4a AF527803
NM 058195
GGTTTTTTTTAGAGG
ATTTGAGGGATA
AAACAAACCCTC
TACCCACCTAA 62
MGMT AL355531 GGGTAATTTGGGAG
GTAT
CTCTCTTACTTTT
CTCAAATCCT 58
MLH-1 U83845 TTAGATTATTTTAGT
AGAGGTATATAAG
ATACCTTCAACC
AATCACCTCAATA 53
Table 2: Primers used in the analysis of methylation at the ampliﬁed CpG islands of bisulﬁte treated DNA by PCR including their sequences
and annealing temperature.
Gene MSP reaction Sense primer Antisense primer Annealing
temp (◦C)
P16
INK4a Unmethylated TTATTAGAGGG
TGGGGTGGATTGT
CAACCCCAAACC
ACAACCATAA 64
Methylated TTATTAGAGGGTGG
GGCGGATCGC
GACCCCCGAACC
GCGACCGTAA 77.5
MGMT Unmethylated TTTGTGTTTTGATGT
TTGTAGGTTTTTGT
AACTCCACACTCT
TCCAAAAACAAAACA 65
Methylated TTTCGACGTTCGTAG
GTTTTCGC
TTTCGACGTTCGT
AGGTTTTCGC 70
MLH-1 Unmethylated TTAATAGGAAGAGT
GGATAGTG
TCTATAAATTACT
AAATCTCTTCA 57
Methylated TTAATAGGAAGAGC
GATAGC
CTATAAATTACTA
AATCTCTTCG 60.5
Table 3: PCR conditions for the ampliﬁcation step.
Step Temperature Duration
Initial denaturation 95◦C4 m i n
Denaturation 95◦C1 m i n × 35
Annealing (Primer speciﬁc) ◦C1 m i n × 35
Synthesis 72◦C1 m i n × 35
Final extension 72◦C7 m i n
Holding 4◦C—
Table 4: PCR conditions for the methylated/unmethylated step.
Step Temperature Duration
Initial denaturation 95◦C4 m i n
Denaturation 95◦C3 0 s e c × 35
Annealing (Primer speciﬁc)◦C3 0 s e c × 35
Synthesis 72◦C1 m i n × 35
Final extension 72◦C3 0 m i n
Holding 4◦C—
signiﬁcant. Results for both MSP and pyrosequencing were
recorded in an SPSS and Excel spreadsheet for statistical
analysis.
2.3. Immunohistochemistry. Immunohistochemistry was
performed on paraﬃne m b e d d e dt i s s u e sf r o m5µMs e c t i o n s
cut on a microtome and mounted on Surgipath positively
charged slides (Peterborough, UK). Automated IHC was
optimised using the TECHMATE 500 (DAKO, UK) and
EnVision (DAKO, UK) detection system. Steam antigen
retrieval was performed for 3 minutes in TRIS EDTA pH
9.0 for MLH-1 and MSH-6 and 0.01mM EDTA for MSH-2,
PMS-2, Ki 67, and CK 20. Antibodies were purchased from
BD pharmingen, concentrations were as follows: MLH-1
1:75, MSH-2 1:200, MSH-6 1:20, Ki-67 1:200, and CK 20
1:200.
In total 167 hyperplastic polyps were analysed: 115
sporadic and 52 familial. A substantially larger number of
sporadic hyperplastic polyp were analysed in comparison to
methylation analysis since many of the smaller polyps either
failed DNA extraction, were too small to consider for DNA
extraction, or did not have adequate tissue in the block to
perform DNA extraction. All polyps tested for methylation
had IHC analysis with all 5 antibodies.
2.4. MSI. A panel of 5 markers: BAT25, BAT 26, NR-21, NR-
24,andMONO-27wereused.Theseareallmono-nucleotide
markers which are considered more sensitive for MSI than
theoriginalpanelofmarkersrecommendedbytheAmerican4 International Journal of Surgical Oncology
Table 5: Pyrosequencing primers for MINT 1 and 31.
Gene Forward Reverse Sequencing Dispensation
MINT
1AF135501
AGGGTTGGAG
AGTAGGGGAGTT
ATCTCCCCTCC
CCTAATTAACA
GCTTGAGGTTT
TTTGTT
CGCTCGTCTCGTATTACTCGT
ATACT
MINT 31
AF135531T
TTGGGGTGGG
AATTGAGA
CCTCACTTA
TTACAAATCC
CCACT
GGAATTGAGAT
GATTTTAATTT ATCTAGCTAGCTAGCTCGA
Joint Commission on Cancer [26, 27]. Microsatellite analysis
was performed using previously described techniques [26,
27].
2.5. Statistics. Comparison between the sporadic and famil-
ial groups were made using the Fisher’s exact test where
n u m b e r sw e r el e s st h a n5o rC h i
2 where numbers exceeded
5. SpSS and Excel software was used to perform statistical
analysis. Correction for multiple comparisons were made.
3. Results
After tissue processing for methylation analysis there were
124 hyperplastic polyps with adequate amounts of DNA.
There were 78 sporadic versus 25 familial polyps and 21
HNPCC polyps. Of the 124 polyps, 17 were from the right
side of the colon (proximal to the splenic ﬂexure) and 96
from the left side of the colon. For 11 polyps there were no
records documenting position. The male-to-female ratio was
1:1, aged 22–78 years (median 47).
The overall incidence of methylation in all hyperplastic
polyps tested were MLH-1 10%, p16INK4a 26%, MGMT
19%, MINT 1 28%, and MINT 31 26%. When CiMP was
calculated for the 124 hyperplastic polyps 36% (n = 45)
were CiMP stable, 34% (n = 42) were CiMP low, and 30%
(n = 37) were CiMP high. This results in an overall CiMP +
rate of 64%.
For the HNPCC group there were no signiﬁcant dif-
ferences in the incidence of methylation in comparison to
the sporadic group except for MINT 31 P = .046 (Fisher’s
exact test). These observations were further conﬁrmed when
comparingCiMPstatuswherenosigniﬁcantdiﬀerenceswere
seen between CiMP low (P = .214), CiMP high (P = .186),
and CiMP + (P = .932) status (Figures 3 and 4).
The familial group demonstrated a signiﬁcantly lower
incidence of methylation of MINT 31 when compared to
the sporadic cohort and nearly reached signiﬁcance for
MLH-1, p16INK4a, and MGMT. When CiMP status was
plotted, signiﬁcant diﬀerences were observed between CiMP
stable, high, and overall CiMP +ve rates. CiMP low did
not demonstrate a signiﬁcant diﬀerence between either the
HNPCC or familial group (Figures 3 and 4).
In total, 17 hyperplastic polyps were right sided. methy-
lation was more frequent in the right side of the colon for
p16INK4a,M I N T1 ,a n dM I N T3 1( P = .019, .010 and .012,
resp., Chi
2)b u tn o tf o rM G M T( P = .518 Fisher’s exact
test) or MLH-1 (P = .199 Fisher’s exact test). Although over
0
10
20
30
40
50
60
MLH-1 p16 MGMT MINT 1 MINT 31
(
%
)
Sporadic
HNPCC
Familial
.061 .087 .146 .005 .794
0.45 0.875 0.55 0.2 0.046
Methylation of sporadic: HNPCC: familial
hyperplastic polyps
Figure 3: Methylation of hyperplastic polyps, sporadic: HNPCC:
familial. P values are in pink boxes. No signiﬁcant diﬀerences
were demonstrated between the sporadic and HNPCC groups. For
MINT 31 there was a signiﬁcant diﬀerence between the familial
and sporadic group. For MLH-1 (MSP), p16INK4a and MGMT the
diﬀerence between the familial and sporadic group nearly reached
signiﬁcance.
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P values (Chi
2) in pink boxes. No signiﬁcant diﬀerence were
observed between the sporadic and HNPCC group (olive boxes).
Comparing the pattern of methylation after scoring CiMP for the
sporadic and familial groups demonstrated a signiﬁcant diﬀerence
for CiMP H and overall CiMP positive status (pink boxes).International Journal of Surgical Oncology 5
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Figure 6: High-powered view of HP showing weak staining with
MLH-1 protein and known MLH-1 methylation.
double the amount of polyps from the right side of the colon
had MLH-1 methylation detected by MSP (9% left versus
19% right) this diﬀerence did not reach signiﬁcance (P =
.199 Fisher’s exact test). However, when CiMP wascompared
between the left and right sides of the colon (Figure 5)C i M P
high was more frequently encountered in HPs from the right
side of the colon (P = .040 Chi
2).
3.1. MSI Hyperplastic Polyps. After methylation analysis
there was enough DNA remaining to perform MSI analysis
on 81 hyperplastic polyps. MSI-H was not detected in
any of the hyperplastic polyps, MSI-L was detected in
3 (5.5%) of the sporadic and 1 (3.7%) of the HNPCC
hyperplastic polyps, these diﬀerences were not signiﬁcant
(Fisher’s exact test 1.00). MLH-1 methylation was found in
all four specimens demonstrating MSI-L.
3.2. Details of Immunohistochemical Analysis of Hyperplastic
Polyps. The results for IHC of the mismatch repair protein
MLH-1, MSH-2, and MSH-6 can be seen in Table 6.N o n e
of the polyps demonstrated complete loss of staining. Weak
staining was encountered with all three antibodies. This was
believed to be related to poor tissue ﬁxation in the majority
of cases. However, those polyps which were methylated
Weak staining
Normal staining
+ve
interstitial
cells
Figure 7: High-powered view demonstrating weak MSH-6 methy-
lation in a hyperplastic polyp.
Table 6: IHC results of hyperplastic polyps for the mismatch repair
proteins.
Staining sporadic/familial MLH-1 MSH-2 MSH-6
Present 97/52 101/49 77/43
Weak 17/0 14/3 38/9
Patchy 1/0 0/0 0/0
Total 115/52 115/52 115/52
Table 7: IHC of hyperplastic polyps.
Crypt staining sporadic/familial Ki 67 CK20
Basal 1/3 50/21 39/18
Middle 1/3 56/28 50/26
Outer 1/3 9/3 26/8
Total 115/52 115/52
at the MLH-1 promoter region frequently showed weak
staining with the MLH-1 antibody (10%; Figure 6). MSH-
6 frequently showed weak staining in 47 (28%) of the
hyperplastic polyps analysed (Figure 7).
The normal pattern of expression for Ki67 is in the base
of the crypts and for CK20 the luminal surface of the crypts.
Staining for Ki67 was predominantly basal or to the middle
third of the crypts, more extensive staining to the outer third
of the crypts was seen in 12/167 cases. Staining for CK20
was predominantly localised to the outer and middle third,
although more extensive staining into the base of the crypts
was seen in over one-third of cases Table 7.
4. Discussion
Analysis of methylation proﬁles of HPs from patients with
a sporadic and familial risk of CRC has not previously
been performed. This study has shown that in an HNPCC
screening program, HPs that occur in those patients with
conﬁrmed mutations or HNPCC on clinical grounds have
no more worrying features at a molecular level than those
patients with HPs in a sporadic setting. Thus, those HPs that
occur in patients with HNPCC could possibly be managed in6 International Journal of Surgical Oncology
the same manner as those that are detected in other clinical
scenarios.
The safety of leaving HPs in HNPCC patients should
be further conﬁrmed as those in a screening program will
receive alternate year colonoscopy. This new data may oﬀer a
novel contribution to the management of HNPCC patients.
If so, patients with HNPCC who have HPs removed can
be reassured these lesions are not manifestations of their
condition. To validate these results a retrospective power
study was performed looking for a 10% diﬀerence between
the sporadic and HNPCC group for CiMP-H based on the
provisional result from this study. This would require 376
patients in each arm to demonstrate a signiﬁcant diﬀerence
(that is, 0.05 with 80% conﬁdence) if it exists. In addition
should such a study be performed incorporating BRAF
mutation analysis of polyp DNA along with methylation
studies could give deﬁnitive conclusions with regards to the
nature of HPs in HNPCC.
The true risk of developing CRC in association with HPs
in either HNPCC or a sporadic setting is still unknown.
Until a large prospective series, similar to the veteran aﬀairs
is performed identifying patients with HPs or SAs and
deﬁning the incidental risk of CRC this question will remain
unanswered.
The control arm of this study contained an unselected
12-month cohort of specimens collected from the pathology
archives at Manchester Royal Inﬁrmary. There are previously
no reports of the incidence of methylation in HPs from such
a cohort. One of the problems with the current data in the
literature is its tendency to report on either patients with
hyperplastic polyposis or selected HPs of a certain size or
location. In this series, 70% of sporadic HPs demonstrated
some degree of methylation (CIMP+); 38% were CIMP-H.
Thisnotonlysupportsthecurrentevidencethatmethylation
isacontributingbiologicalmechanisminHPsformationbut
also demonstrates its high frequency.
All those MSI-L HPs demonstrated MLH-1 promoter
methylation. This supports the hypothesis that HPs rather
than adenomas may be the precursor to those MSI+ve
sporadic CRCs in the right side of the colon. The association
of MSI-L with partial methylation of the MLH-1 promoter
h a sb e e nr e p o r t e db e f o r e[ 28] and may, in a graded fashion,
represent a rate limiting step in progression to CRC or
contribute to malignant progression [29].
T w op a p e r sh a v er e p o r t e da na s s o c i a t i o no fC I M Pa n d
MLH-1 methylation in patients with CRC and a family
history of CRC [30, 31]. Intuitively it is appealing to consider
methylation as a factor increasing an individual’s risk of CRC
via the serrated pathway in the context of familial CRC due
to the association of environmental factors and acquired
epigenetic changes. However, in this series less methylation
was encountered in the familial group.
5. Conclusions
This study has shown that in an HNPCC screening program,
HPs that occur in those patients with conﬁrmed mutations
or HNPCC on clinical grounds have no more worrying
features at a molecular level than those patients with HPs
in a sporadic setting. This study has also conﬁrmed that
methylation is a common biological event in sporadic HPs.
There is a need for longitudinal studies and biological
proﬁling of HPs to clarify the true risk of these lesions
progressing to CRC.
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